Anders Grubb
131 – 140 of 350
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Glycemic and non-glycemic effects of pioglitazone in triple oral therapy in patients with type 2 diabetes mellitus
(
- Contribution to journal › Article
-
Mark
Standardization of p-creatinine assays and use of lean body mass allow improved prediction of calculated glomerular filtration rate in adults: A new equation
(
- Contribution to journal › Article
-
Mark
Checking the conformational stability of cystatin C and its L68Q variant by molecular dynamics studies: Why is the L68Q variant amyloidogenic?
(
- Contribution to journal › Article
- 2005
-
Mark
Lack of the Cysteine-Protease Inhibitor Cystatin C Promotes Atherosclerosis in Apolipoprotein E-Deficient Mice.
(
- Contribution to journal › Article
-
Mark
In search of selective inhibitors of cysteine protease, cathepsin K
(
- Contribution to journal › Article
-
Mark
Cystatin C modulates neurodegeneration and neurogenesis following status epilepticus in mouse
(
- Contribution to journal › Article
-
Mark
Cystatin C as a marker of GFR - history, indications, and future research
(
- Contribution to journal › Scientific review
-
Mark
Cystatin C Deficiency Increases Elastic Lamina Degradation and Aortic Dilatation in Apolipoprotein E-Null Mice.
(
- Contribution to journal › Article
-
Mark
A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula.
(
- Contribution to journal › Article
-
Mark
Nt-proANP in plasma, a marker of salt sensitivity, is reduced in type 2 diabetes patients.
(
- Contribution to journal › Article